Welcome to our dedicated page for BRII BIOSCIENCES news (Ticker: BRIBY), a resource for investors and traders seeking the latest updates and insights on BRII BIOSCIENCES stock.
Brii Biosciences Limited ("Brii Bio," BRIBY) generates frequent news flow centered on its efforts to develop therapies for major public health challenges, with a particular focus on achieving a functional cure for chronic hepatitis B virus (HBV) infection. Company press releases regularly cover progress across multiple Phase 2 and Phase 2b clinical trials, regulatory milestones and strategic collaborations.
Investors and observers following BRIBY news can expect detailed updates on key HBV programs built around BRII-179, elebsiran (BRII-835, VIR-2218) and tobevibart (BRII-877). Brii Bio often reports new data from studies such as ENSURE, ENRICH and ENHANCE, including end-of-treatment and follow-up results on HBsAg loss rates, the contribution of siRNA on top of pegylated interferon alpha, and the role of BRII-179 in identifying patients more likely to respond to curative regimens. These announcements are frequently timed with major scientific meetings, including EASL, APASL and AASLD conferences.
Beyond HBV, Brii Bio’s news also highlights developments in its broader infectious disease pipeline. This includes clinical and partnering updates for BRII-693, a novel synthetic lipopeptide targeting multidrug- and extensively drug-resistant gram-negative infections, and information on licensing and technology transfer agreements with partners such as Joincare Group and VBI Vaccines, Inc. The company additionally reports on regulatory designations, cash position, cost management measures and share repurchase activities, providing context on its financial and strategic posture.
For those tracking BRIBY, the news stream offers insight into how Brii Bio is advancing late-stage HBV programs, expanding its anti-infective portfolio and managing partnerships and capital to support long-term development plans.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Brii Biosciences Limited reported its fiscal year 2022 results, highlighting a revenue increase to RMB51.6 million due to the COVID-19 therapy commercialization in China. The company is focused on advancing its clinical programs for hepatitis B and depression, with Phase 2 trials set for 2023. Financially, R&D expenses decreased by 10.9% to RMB440.6 million, while total comprehensive expense fell by 94.4% to RMB238.5 million. Brii Bio discontinued its COVID-19 antibody program to prioritize its main clinical projects and remains well-funded through 2025.